lu-177-dgul
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 12, 2021 (NCT05547061)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07244393 | Phase 1 | Dec 31, 2025 | Cellbion Co., Ltd., Merck |
| NCT05547061 | Phase 1/Phase 2 (Phase 2) | Apr 12, 2021 | Cellbion Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellbion Co., Ltd. | For profit | 2 | 2 | 2 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1